Supply Chain Strategy forEmerging Pharmaceutical Companies

Bringing 31 years of Pfizer's supply chain, formulation development, manufacturing and sourcing expertise to emerging pharmaceutical companies navigating clinical development through commercial launch.

Learn more
Francis Dumont
1+
Years inPharmaceutical Sciences
1
Years atPfizer
2023
Interviewed inOutsourced Pharma
2013
Published inPharmaceutical Engineering
2011
Published inPharmaceutical Outsourcing

Worked with

01The Challenge

Great science doesn't guarantee great manufacturing

Emerging pharmaceutical companies face complex decisions about CDMO selection, vendor relationships, and supply chain strategy without decades of institutional knowledge to guide them.

02Who I Work With

This might be a fit if...

  • You're an emerging pharmaceutical or biotech company moving from preclinical to clinical development

  • You need strategic guidance on CDMO selection and vendor relationship management, not just tactical execution

  • You're planning for commercial launch and need someone who understands the full development arc

  • You want to integrate environmental sustainability into your manufacturing approach from the start

  • You value decades of institutional knowledge from someone who managed Pfizer's external drug product supply strategy

  • You need due diligence support for CDMO business development or partnership evaluation

I work best with emerging pharmaceutical and biotech companies who are serious about building robust supply chains from the beginning.

Sound like you? Let's talk

03How We Work Together

Focused advisory for pharmaceutical development

Structured engagements built around your stage of development and specific sourcing challenges

4–6 Weeks

Sourcing Analysis & Strategy

Rapid assessment of your current supply chain approach with strategic recommendations for CDMO selection, vendor qualification, and manufacturing partnerships aligned to your development timeline.

  • CDMO landscape analysis for your product requirements
  • Vendor qualification criteria and evaluation framework
  • Supply strategy recommendations from clinical through commercial
  • Risk assessment and mitigation plan
Get started
Popular
6–12 Months

Development Through Commercialization Advisory

Ongoing strategic advisory as you move through clinical phases and prepare for commercial launch. Includes vendor relationship management, supply chain optimization, and integration support.

  • Vendor relationship oversight and performance management
  • Technology evaluation for drug delivery and formulation
  • Commercial readiness assessment and launch preparation
  • Integration support for acquisitions or partnerships
Get started
2–4 Weeks

CDMO Due Diligence & Business Development

Technical and operational due diligence for CDMO partnerships, acquisitions, or business development opportunities. Leverages deep understanding of manufacturing capabilities, quality systems, and operational readiness.

  • Technical capability assessment
  • Quality systems and GMP compliance review
  • Operational readiness evaluation
  • Strategic fit analysis and recommendations
  • Integration planning for partnerships or acquisitions
Get started

04The Approach

Strategic guidance built on decades of experience

Step 1 of 5

Discovery & Assessment

Deep dive into your product, development stage, current supplier relationships, and manufacturing requirements. Understanding your timeline and constraints shapes the strategic recommendations.

Duration1-2 weeks
FocusCurrent State
OutputSituation Analysis

05Experience

Selected Work

01Pharmaceutical · 2010–2023
Pfizer Global Research & Development

Built and led external drug product supply strategy across clinical through early launch portfolios

13Years Leading Sourcing

Challenge

Pfizer needed comprehensive oversight of external manufacturing vendor relationships across the full development lifecycle, from clinical trial supplies through commercial launch, including integration of acquired and in-licensed compounds.

Approach

Developed vendor management processes, led strategic sourcing initiatives for novel manufacturing approaches (including aseptic vendor strategy and novel technology development), and established performance management frameworks for global CDMO partnerships.

Outcome

Managed vendor base supporting Pfizer's global clinical portfolio, implemented process improvements for external manufacturing, and led supply integration for multiple acquisitions including biologics-based company integration.

02Pharmaceutical · 2000–2003
Pfizer Drug Delivery Technology Assessment

Led pharmaceutical sciences coordination for drug delivery technology evaluation

10+Feasibility Programs Managed
2IND Filings Supported

Challenge

Evaluating external drug delivery technologies and managing feasibility programs required cross-functional coordination across Pharmaceutical R&D, Analytical R&D, Chemistry, QA, Regulatory CMC, and external alliance management.

Approach

Served as Pharmaceutical Sciences Project Coordinator from preclinical through Phase 2 development, managed collaboration partnership, coordinated all technical meetings and IND filing preparation, and established drug delivery contact database.

Outcome

Successfully coordinated multiple interdisciplinary project teams, managed technical aspects of numerous feasibility programs, and contributed to internal research initiatives for parenteral depot systems.

03Biotechnology
Biotech Client

Dosage form refinement and supply chain establishment

Challenge

An emerging biotech company with an innovative approach to existing medication needed to select a dosage form and suppliers to progress the project.

Approach

Helped the client narrow the dosage form to a fit-for-purpose one that met the medical needs, with consideration for financial, regulatory and sourcing aspects. Managed one of their ongoing supplier relationships and provided analysis of outcomes. Once the target dosage form was solidified based on my recommendations, I led a comprehensive sourcing evaluation and supplier selection process.

Outcome

The client now has a robust dosage form to progress, as well as a reputable, globally acceptable supplier to manufacture and advance the project.

06Testimonials

What collaborators say

Fran is wonderful to work with. He has elevated our development plans and strategic focus tremendously with his experience, know-how and connections. He has become a truly valued part of our team in a short amount of time.

Koen
Co-founder, Angiomedix

Fran has extensive experience across the pharmaceutical industry, with a strong track record spanning development, manufacturing, sourcing, and supply strategy. His breadth of experience gives him a clear understanding of both the technical and commercial considerations that shape development programs and sourcing decisions. I have known Fran for many years and have consistently valued his industry perspective and judgment and would highly recommend him to organizations looking for experienced, practical guidance across pharmaceutical development and supply.

Peter Stolba
Chief Business Officer, Artis BioSolutions

07About

Francis Dumont

Francis Dumont

Francis is an independent pharmaceutical development professional providing advisory and consulting support in strategic sourcing, clinical development through commercialization, environmental sustainability, and CDMO business development and due diligence. He has served on the advisory boards of AEQUOR, Inc. (focused on innovative healthcare and antibiofilm solutions) and Karmanterra (focused on reducing atmospheric carbon dioxide through innovative agricultural approaches).

Since retiring from Pfizer in 2023, Francis brings 31 years of experience across pharmaceutical sciences. As Senior Director of External Drug Product Supply Strategy, he influenced supplier relationships from development through commercial launch. His career included leading global sourcing teams, overseeing clinical trial product manufacturing, supporting clinical-scale sterile manufacturing facilities, evaluating drug delivery technologies, and developing formulations. Earlier, he held environmental science roles conducting site characterization and remediation across multiple U.S. locations.

Based in Southern California since 2017 after 25 years at Pfizer’s Groton, Connecticut site, Francis has published on vendor networks for clinical supply manufacturing services in Pharmaceutical Outsourcing and Pharmaceutical Engineering. His approach combines decades of Pfizer external supply strategy experience with a commitment to environmental sustainability and innovative collaboration that helps emerging companies reach their full potential.

08Career

From analytical chemistry to global supply strategy

Nine roles, from a lab bench in 1987 to independent advisory today.

Now

2023 to present

  1. 2023 to present

    Independent Advisor and Consultant

    Self-employed

    1
  2. 2024 to 2026

    Advisory Board Member

    AEQUOR, Inc.

    2
  3. 2023 to 2025

    Advisory Board Member

    Karmanterra

    3
  4. 2019 to 2023

    Senior Director, Drug Product Supply External Strategy

    Pfizer

    4
  5. 2013 to 2019

    Senior Director and Head of Drug Product Supply Sourcing

    Pfizer

    5
  6. 2010 to 2013

    Director and Head of Clinical Supply Sourcing

    Pfizer

    6
  7. 1992 to 2010

    Multiple staff and managerial roles, Pharmaceutical Sciences

    Pfizer

    7
  8. 1990 to 1992

    Environmental Chemist

    Atlantic Environmental Science

    8
  9. 1987 to 1988

    Analytical Chemist

    Environmental Science Corporation

    9

Common Questions

Get in Touch

Ready to build
your supply strategy?

Whether you're evaluating CDMOs for your first clinical trial or preparing for commercial launch, let's discuss how strategic sourcing expertise can accelerate your path forward.

Carlsbad, California • Available for remote or in-person engagements